drugset / Trial / NCT07010822
A Study to Evaluate the Mucosal Intestinal Immunity to Poliovirus Type-2 of nOPV2 at Birth Dose in Healthy IPV Vaccinated Infants
Phase 3
Not yet recruiting
740 enrolled
Fidec Corporation
Bill and Melinda Gates Foundation · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The study will compare the transmissible levels of poliovirus type-2 detected in stool samples collected at the time of the nOPV2 challenge and subsequent timepoints in 3 groups of newborns receiving an nOPV2 dose at birth and primed with 3 doses of IPV (6 - 10 - 14 weeks of age).
Timeline
- Start
- 2025-12-08
- Primary completion
- 2026-09-21
- Completion
- 2026-09-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | nOPV2 | Vaccine | — | — |